
Avecho’s rally reflects Phase III CBD-insomnia progress, patent wins, and improving investor confidence. The biotech commercialises its TPM delivery platform across pharma, skincare, and animal health, while its production business supports higher-risk human health programs.

Artrya (ASX: AYA) is consolidating after a strong rally as investors assess its U.S. expansion, FDA progress, and commercial rollout of the AI-powered Salix platform. Despite the pullback, growing adoption and clinical milestones continue to support its long-term growth outlook.

Ansell (ASX: ANN) delivers double‑digit earnings growth, disciplined cost control, and strong cash conversion amid subdued market conditions, reinforcing margin resilience and balance‑sheet strength.

Challenger (ASX: CGF) delivers disciplined growth and capital strength, positioning itself as Australia’s leading retirement‑income compounder with expanding annuity sales, resilient margins and a robust balance sheet.

Weebit Nano is gaining investor attention as commercial progress accelerates. Licensing deals, JEDEC qualification, product tape-outs, stronger revenue, and fresh funding have boosted confidence. At the same time, the share price remains technically strong with buyers defending key support levels after a significant breakout.

Solstice Minerals has gained momentum after strong drilling results at its Nanadie copper-gold project. The explorer is expanding its resource potential, backed by fresh funding, multiple exploration targets, and a bullish share price breakout supported by rising trading volume.
...